Improvements with sublingual house dust mite immunotherapy in allergic rhinitis.

Corresponding Author:
Dr Brian Lipworth MD.
Scottish Centre for Respiratory Research
Ninewells Hospital and Medical School
University of Dundee, Scotland UK

b.j.lipworth@dundee.ac.uk
Tel: 01382 383188 Fax: 01382 383259

Keywords: immunotherapy; allergic rhinitis; house dust mite
To the Editor,

The results of Demoly et al\textsuperscript{1} demonstrate promising effects of two doses of the house dust mite sublingual tablet in allergic rhinitis, with mean improvements in the primary outcome of the total combined rhinitis score (TCRS) exceeding the minimal clinically important difference (MCID) of 1.0. However on inspection of the 95% confidence intervals, it is evident that the lower bounds for improvements in TCRS were less than the MCID: reported changes from placebo were 0.45 (6.7% difference) and 0.49 (7.2% difference) for 6 and 12 SQ-HDM doses respectively, inferring that such responses were statistically significant but perhaps not so clinically meaningful\textsuperscript{2}. Pointedly no clinically relevant improvements were observed in disease specific quality of life score. This in turn begs the question as to whether similar improvements would be seen with SQ-HDM in patients with persistent allergic rhinitis who were optimally treated with conventional pharmacotherapy.

Dr Brian Lipworth MD. Scottish Centre for Respiratory Research, Ninewells Hospital and Medical School, University of Dundee, Scotland UK

b.j.lipworth@dundee.ac.uk

References